In this multicenter, retrospective cohort study, we found that patients treated with first-line afatinib for advanced lung adenocarcinoma harboring susceptible EGFR mutations benefited from add-on LCT, leading to better PFS and OS. The gene discussed is EGFR; the disease is lung adenocarcinoma.